Hyloris Developments SA

13 patents currently held · Updated Nov 14, 2026

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

May 2029

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Dec 6, 2026
The maintenance fee for Tranexamic Acid Oral Solution (US 11,666,532) comes due Dec 6, 2026. Unpaid by Jun 7, 2027, it lapses early.
1 fee due Oct 16, 2027
The maintenance fee for Method of Initiating or Escalating Dofetilide Dose and Formulations Therefor (US 11,957,648) comes due Oct 16, 2027. Unpaid by Apr 17, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

1 of the patents on this record was granted since Aug 16, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Patent	Title	Status	Expires	Confidence
US 7,923,447	Parenteral solutions containing metolazone In force Term ends May 18, 2029 · From the USPTO record	In force	Term ends May 18, 2029	From the USPTO record
US 9,427,398	Parenteral solutions containing metolazone In force Term ends Jun 5, 2030 · From the USPTO record	In force	Term ends Jun 5, 2030	From the USPTO record
US 11,389,451	Metolazone Emulsion Formulation In force Term ends Nov 1, 2038 · High confidence	In force	Term ends Nov 1, 2038	High confidence
US 12,121,520	Metolazone emulsion formulation In force Term ends Dec 4, 2038 · From the USPTO record	In force	Term ends Dec 4, 2038	From the USPTO record
US 11,666,532	Tranexamic Acid Oral Solution In force Term ends Jan 9, 2039 · High confidence	In force	Term ends Jan 9, 2039	High confidence
US 11,413,241	METHOD FOR PREPARING A COMPOSITION WITH A LOW DISSOLVED OXYGEN CONTENT, COMPRISING ACETAMINOPHEN, AND OPTIONALLY ONE OR MORE NSAIDs, AND A COMPOSITION OBTAINED THEREOF In force Term ends Jan 29, 2039 · High confidence	In force	Term ends Jan 29, 2039	High confidence
US 11,364,213	Method of Initiating or Escalating Dofetilide Dose and Formulations Therefor In force Term ends May 6, 2040 · High confidence	In force	Term ends May 6, 2040	High confidence
US 11,957,648	Method of Initiating or Escalating Dofetilide Dose and Formulations Therefor In force Term ends Sep 22, 2040 · High confidence	In force	Term ends Sep 22, 2040	High confidence
US 12,343,320	Intraveneous dofetilide to reduce the risk of developing AF/AFL post coronary bypass surgery In force Term ends Jan 31, 2043 · From the USPTO record	In force	Term ends Jan 31, 2043	From the USPTO record
US 12,521,357	Intravenous Dofetilide to Convert Atrial Fibrillation/Flutter In force Term ends Feb 28, 2043 · High confidence	In force	Term ends Feb 28, 2043	High confidence

10 of 13 patents shown.

Pro members see all 13.

Pro members: see all 13 patents

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

3 pending · 3 abandoned · 2 no status recorded

List them